AstraZeneca In $5.3bn AI Drug Discovery Deal With China’s CSPC

Anglo-Swedish pharmaceutical giant AstraZeneca has concluded a deal worth up to $5.3 billion (£3.9bn) with China’s CSPC Pharmaceutical to use AI technology to help develop oral drugs for a range of chronic health conditions.

The deal includes an upfront payment of $110m to Hong Kong-listed CSPC, which said it would use its AI-driven, dual-engine drug discovery platform to analyse the binding patterns of target proteins with existing compound molecules to identify those with the highest chance of success in clinical trials.

Sharon Barr, head of biopharmaceuticals R&D at AstraZeneca, said the collaboration showed the firm’s “commitment to innovation” to tackle chronic diseases that affect more than two billion people worldwide.

Image credit: AstraZeneca

AI-driven deal

“Forming strong collaborations allows us to leverage our complementary scientific expertise to support the rapid discovery of high-quality novel therapeutic molecules to deliver the next-generation medicines,” Barr said.

The companies said they would be working on preclinical candidates for multiple targets with the potential “to treat diseases across chronic indications” including a therapy for immunological diseases, without giving further details of the specific conditions they would be targeting.

Under the deal CSPC is eligible for up to $1.62bn in potential development milestone payments and up to $3.6bn in sales milestones in addition to single-digit royalties if any resulting drugs should arrive at market.

AstraZeneca previously licensed the Shijiazhuang-based biotech firm’s preclinical cardiovascular disease drug for a $100m upfront payment last October.

China strategy

As part of plans to further its ambitions in China AstraZeneca recently announced a global strategic research and development centre in Beijing as part of a $2.5bn investment in the city.

The company’s plans in the region were clouded when Chinese authorities detained its former China head Leon Wang last year as part of an investigation into potential illegal drug importation.

Matthew Broersma

Matt Broersma is a long standing tech freelance, who has worked for Ziff-Davis, ZDnet and other leading publications

Recent Posts

Meta ‘Unlikely’ To Make Further Changes For EU

Facebook parent Meta reportedly not planning further changes to comply with EU rules, making it…

14 hours ago

France Opens Formal Probe Into X ‘Foreign Interference’

French public prosecutor's office opens formal investigation into allegations that X algorithm favours foreign interference

15 hours ago

Tesla Plans Robotaxi Launches In California, Arizona

Tesla pushing ahead with expansion of autonomous taxi service, California offering will initially only roll…

16 hours ago

Huawei Launches Pura 80 Smartphone Range In Dubai

Huawei holds international launch for Pura 80 smartphones as it seeks renewed expansion for once-massive…

16 hours ago

Huang Sells Stock As Nvidia Value Hits $4tn

Nvidia becomes first company ever to reach $4tn market valuation, helping give Huang net worth…

17 hours ago

Police Arrest Four Linked To M&S, Co-op Attacks

Police arrest three males and one woman in connection with cyber-attacks earlier this year that…

17 hours ago